ID30046A - Kemoterapi kanker dengan asetildinalina digabung dengan gemsitabina, kapestabina atau kisplatin - Google Patents

Kemoterapi kanker dengan asetildinalina digabung dengan gemsitabina, kapestabina atau kisplatin

Info

Publication number
ID30046A
ID30046A IDW20010901A ID20010901A ID30046A ID 30046 A ID30046 A ID 30046A ID W20010901 A IDW20010901 A ID W20010901A ID 20010901 A ID20010901 A ID 20010901A ID 30046 A ID30046 A ID 30046A
Authority
ID
Indonesia
Prior art keywords
gemsitabina
capestabine
cancererapy
acethylinineine
cisplatin
Prior art date
Application number
IDW20010901A
Other languages
English (en)
Inventor
William R Grove
Wayne D Klohs
Ronald Lynn Merriman
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ID30046A publication Critical patent/ID30046A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IDW20010901A 1998-09-25 1999-07-08 Kemoterapi kanker dengan asetildinalina digabung dengan gemsitabina, kapestabina atau kisplatin ID30046A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10180998P 1998-09-25 1998-09-25

Publications (1)

Publication Number Publication Date
ID30046A true ID30046A (id) 2001-11-01

Family

ID=22286531

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010901A ID30046A (id) 1998-09-25 1999-07-08 Kemoterapi kanker dengan asetildinalina digabung dengan gemsitabina, kapestabina atau kisplatin

Country Status (34)

Country Link
US (3) US6469058B1 (id)
EP (1) EP1115391B1 (id)
JP (1) JP2002525320A (id)
KR (1) KR20010075348A (id)
CN (1) CN1319009A (id)
AP (1) AP2001002109A0 (id)
AT (1) ATE225655T1 (id)
AU (1) AU762079B2 (id)
BG (1) BG105470A (id)
BR (1) BR9913952A (id)
CA (1) CA2342981A1 (id)
CZ (1) CZ2001905A3 (id)
DE (1) DE69903458T2 (id)
DK (1) DK1115391T3 (id)
EA (1) EA200100369A1 (id)
EE (1) EE200100187A (id)
ES (1) ES2185378T3 (id)
GE (1) GEP20043199B (id)
HK (1) HK1040190A1 (id)
HR (1) HRP20010225B1 (id)
HU (1) HUP0103640A3 (id)
ID (1) ID30046A (id)
IL (1) IL141951A0 (id)
IS (1) IS5888A (id)
NO (1) NO20011493L (id)
NZ (1) NZ510504A (id)
OA (1) OA11659A (id)
PL (1) PL348673A1 (id)
PT (1) PT1115391E (id)
SK (1) SK3602001A3 (id)
TR (1) TR200100859T2 (id)
WO (1) WO2000018393A1 (id)
YU (1) YU22401A (id)
ZA (1) ZA200102233B (id)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2001002109A0 (en) * 1998-09-25 2001-03-31 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
US7850990B2 (en) * 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20080075762A1 (en) * 2001-10-03 2008-03-27 Paul Tardi Compositions for delivery of drug combinations
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20040132825A1 (en) * 2002-03-04 2004-07-08 Bacopoulos Nicholas G. Methods of treating cancer with HDAC inhibitors
ES2532607T3 (es) * 2002-03-04 2015-03-30 Merck Hdac Research, Llc Métodos de inducción de la diferenciación terminal
US7456219B2 (en) * 2002-03-04 2008-11-25 Merck Hdac Research, Llc Polymorphs of suberoylanilide hydroxamic acid
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
US8026216B2 (en) 2002-10-24 2011-09-27 Spectrum Pharmaceuticals, Inc. Methods and compositions for contributing to the treatment of cancers
US20070032422A1 (en) 2002-10-24 2007-02-08 Spectrum Pharmaceuticals, Inc. Methods, compositions and articles of manufacture for contributing to the treatment of cancers
GB0226434D0 (en) * 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
MXPA05003431A (es) * 2002-11-15 2005-07-05 Warner Lambert Co Quimioterapia de combinacion.
US20060165744A1 (en) * 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations
PE20050206A1 (es) * 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
CN100431606C (zh) * 2004-11-22 2008-11-12 山东蓝金生物工程有限公司 一种抗癌药物组合物
US7957507B2 (en) 2005-02-28 2011-06-07 Cadman Patrick F Method and apparatus for modulating a radiation beam
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
US8232535B2 (en) 2005-05-10 2012-07-31 Tomotherapy Incorporated System and method of treating a patient with radiation therapy
US7643661B2 (en) * 2005-07-22 2010-01-05 Tomo Therapy Incorporated Method and system for evaluating delivered dose
JP2009502255A (ja) * 2005-07-22 2009-01-29 トモセラピー・インコーポレーテッド 治療プランのデリバリにおける品質保証基準を評価するための方法およびシステム
EP2532386A3 (en) 2005-07-22 2013-02-20 TomoTherapy, Inc. System for delivering radiation therapy to a moving region of interest
US8229068B2 (en) 2005-07-22 2012-07-24 Tomotherapy Incorporated System and method of detecting a breathing phase of a patient receiving radiation therapy
US8442287B2 (en) 2005-07-22 2013-05-14 Tomotherapy Incorporated Method and system for evaluating quality assurance criteria in delivery of a treatment plan
EP1906827A4 (en) 2005-07-22 2009-10-21 Tomotherapy Inc SYSTEM AND METHOD FOR EVALUATING THE DOSE USED BY A RADIATION THERAPY SYSTEM
WO2007014090A2 (en) 2005-07-23 2007-02-01 Tomotherapy Incorporated Radiation therapy imaging and delivery utilizing coordinated motion of gantry and couch
RU2009111605A (ru) 2006-08-31 2010-10-10 Спектрум Фармасьютикалз, Инк. (Us) Сенсибилизация опухолевых клеток к лучевой терапии посредством введения агонистов эндотелина
KR101560339B1 (ko) * 2008-01-28 2015-10-14 나노캐리어 가부시키가이샤 의약 조성물 또는 조합제
FR2937867B1 (fr) * 2008-11-03 2011-03-04 Biorebus Association pharmaceutique contenant l acide lipoique et l acide hydroxycitrique a titre de principes actifs.
CA2757743C (en) 2009-04-06 2017-10-10 Eisai Inc. (2'-deoxy-ribofuranosyl)-1,3,4,7-tetrahydro-(1,3) diazepin-2-0ne derivatives for treating cancer
WO2012003413A1 (en) * 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
US8691875B2 (en) 2011-07-01 2014-04-08 Broad Institute, Inc. Solid forms of tacedinaline
US9308235B2 (en) 2012-05-09 2016-04-12 Spectrum Pharmaceuticals, Inc. Treatment of primary and metastatic carcinoma
EP2711009A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. Compounds for use in treating or preventing primary and metastatic breast and prostate cancer
EP2711008A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
EP2711007A1 (en) 2012-09-19 2014-03-26 Institut Univ. de Ciència i Tecnologia, S.A. 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
CN107469240B (zh) 2013-02-26 2020-04-21 安科锐公司 多叶准直器和用于准直治疗放射束的系统
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
US11987579B2 (en) 2018-07-30 2024-05-21 Duke University Niclosamide analogues and therapeutic use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562925A (en) * 1970-04-20 1996-10-08 Research Corporation Tech. Inc. Anti-tumor method
NZ219974A (en) * 1986-04-22 1989-08-29 Goedecke Ag N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
WO1998047500A1 (en) 1997-04-24 1998-10-29 Warner-Lambert Company Use of acetyldinaline for the manufacture of a medicament for the treatment of renal cell carcinoma
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
AP2001002109A0 (en) * 1998-09-25 2001-03-31 Warner Lambert Co Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin.

Also Published As

Publication number Publication date
AU762079B2 (en) 2003-06-19
BG105470A (en) 2001-12-29
DE69903458T2 (de) 2003-07-10
HRP20010225A2 (en) 2002-04-30
IS5888A (is) 2001-03-14
HUP0103640A3 (en) 2003-01-28
IL141951A0 (en) 2002-03-10
EP1115391A1 (en) 2001-07-18
NZ510504A (en) 2003-09-26
GEP20043199B (en) 2004-03-25
PL348673A1 (en) 2002-06-03
WO2000018393A1 (en) 2000-04-06
OA11659A (en) 2004-12-08
CA2342981A1 (en) 2000-04-06
NO20011493D0 (no) 2001-03-23
US6469058B1 (en) 2002-10-22
CZ2001905A3 (cs) 2001-08-15
HRP20010225B1 (en) 2004-10-31
PT1115391E (pt) 2003-02-28
ZA200102233B (en) 2002-06-18
EE200100187A (et) 2002-08-15
EP1115391B1 (en) 2002-10-09
KR20010075348A (ko) 2001-08-09
ATE225655T1 (de) 2002-10-15
JP2002525320A (ja) 2002-08-13
BR9913952A (pt) 2001-06-12
AP2001002109A0 (en) 2001-03-31
SK3602001A3 (en) 2002-07-02
DK1115391T3 (da) 2003-02-10
CN1319009A (zh) 2001-10-24
TR200100859T2 (tr) 2001-08-21
ES2185378T3 (es) 2003-04-16
EA200100369A1 (ru) 2001-10-22
YU22401A (sh) 2004-03-12
AU5092199A (en) 2000-04-17
US20030086965A1 (en) 2003-05-08
HK1040190A1 (zh) 2002-05-31
US20030170300A1 (en) 2003-09-11
NO20011493L (no) 2001-05-23
DE69903458D1 (de) 2002-11-14
HUP0103640A2 (en) 2002-06-29

Similar Documents

Publication Publication Date Title
ID30046A (id) Kemoterapi kanker dengan asetildinalina digabung dengan gemsitabina, kapestabina atau kisplatin
LU93311I2 (fr) Mancozèbe, valifenalate
CU23049A3 (es) Dihidropirimidinas.
IT1312540B1 (it) Composto.
IT1307274B1 (it) Fibbia.
IS5969A (is) Samsett lyfjameðferð
IT1307057B1 (it) Fibbia.
NL1013360A1 (nl) Bouwkundige afscherming.
ID26184A (id) Hidrogenase alfa, omega-dinitril alifatik
IT1306882B1 (it) Innesto elettromagnetico.
DE69805858D1 (de) Geschlossene wulstkonstruktion
NO995727D0 (no) Baereanordning
IT1304039B1 (it) Gommatore.
IT1308896B1 (it) Innesto elettromagnetico.
BR9908946B1 (pt) forração.
NO306323B1 (no) Kokeapparat
ES1040892Y (es) Luminaria empotrable.
ES1041377Y (es) Lampara.
ES1041087Y (es) Lampara.
ES1039687Y (es) Linterna.
ES1040945Y (es) Cocedor.
ES1042604Y (es) Conjunto de iluminacion.
ES1040633Y (es) Escalifono.
ES1040731Y (es) Gafa.
ES1040343Y (es) Carrito portafregona.